These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Tenofovir/emtricitabine metabolites and endogenous nucleotide exposures are associated with p16(INK4a) expression in subjects on combination therapy. Dumond JB; Francis O; Cottrell M; Trezza C; Prince HM; Mollan K; Sykes C; Torrice C; White N; Malone S; Wang R; Van Dam C; Patterson KB; Hudgens MG; Sharpless NE; Forrest A Antivir Ther; 2016; 21(5):441-5. PubMed ID: 26731175 [TBL] [Abstract][Full Text] [Related]
3. Model Linking Plasma and Intracellular Tenofovir/Emtricitabine with Deoxynucleoside Triphosphates. Chen X; Seifert SM; Castillo-Mancilla JR; Bushman LR; Zheng JH; Kiser JJ; MaWhinney S; Anderson PL PLoS One; 2016; 11(11):e0165505. PubMed ID: 27832147 [TBL] [Abstract][Full Text] [Related]
4. Concentrations of Pro-Inflammatory Cytokines Are Not Associated with Senescence Marker p16INK4a or Predictive of Intracellular Emtricitabine/Tenofovir Metabolite and Endogenous Nucleotide Exposures in Adults with HIV Infection. Maas BM; Francis O; Mollan KR; Lee C; Cottrell ML; Prince HM; Sykes C; Trezza C; Torrice C; White N; Malone S; Hudgens MG; Sharpless NE; Dumond JB PLoS One; 2016; 11(12):e0168709. PubMed ID: 28036343 [TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetic Analysis of the Model-Based Pharmacokinetics of Five Anti-HIV Drugs: How Does This Influence the Effect of Aging? Chen J; Akhtari FS; Wagner MJ; Suzuki O; Wiltshire T; Motsinger-Reif AA; Dumond JB Clin Transl Sci; 2018 Mar; 11(2):226-236. PubMed ID: 29205871 [TBL] [Abstract][Full Text] [Related]
6. Intracellular Tenofovir and Emtricitabine Anabolites in Genital, Rectal, and Blood Compartments from First Dose to Steady State. Seifert SM; Chen X; Meditz AL; Castillo-Mancilla JR; Gardner EM; Predhomme JA; Clayton C; Austin G; Palmer BE; Zheng JH; Klein B; Kerr BJ; Guida LA; Rower C; Rower JE; Kiser JJ; Bushman LR; MaWhinney S; Anderson PL AIDS Res Hum Retroviruses; 2016; 32(10-11):981-991. PubMed ID: 27526873 [TBL] [Abstract][Full Text] [Related]
7. Differential extracellular, but similar intracellular, disposition of two tenofovir formulations in the male genital tract. Dumond JB; Greene SA; Prince HMA; Chen J; Maas BM; Sykes C; Schauer AP; Blake KH; Nelson JAE; Gay CL; Kashuba ADM; Cohen MS Antivir Ther; 2019; 24(1):45-50. PubMed ID: 30375984 [TBL] [Abstract][Full Text] [Related]
8. Impact of pharmacogenetics and pregnancy on tenofovir and emtricitabine pharmacokinetics. Gini J; Olagunju A; Dickinson L; Waitt C; Neary M; Else LJ; Siccardi M; Khoo S Pharmacogenomics; 2019 Mar; 20(4):217-223. PubMed ID: 30767719 [TBL] [Abstract][Full Text] [Related]
9. Emtricitabine-Triphosphate in Dried Blood Spots as a Marker of Recent Dosing. Castillo-Mancilla J; Seifert S; Campbell K; Coleman S; McAllister K; Zheng JH; Gardner EM; Liu A; Glidden DV; Grant R; Hosek S; Wilson CM; Bushman LR; MaWhinney S; Anderson PL Antimicrob Agents Chemother; 2016 Nov; 60(11):6692-6697. PubMed ID: 27572401 [TBL] [Abstract][Full Text] [Related]
10. Tenofovir diphosphate and emtricitabine triphosphate concentrations in blood cells compared with isolated peripheral blood mononuclear cells: a new measure of antiretroviral adherence? Adams JL; Sykes C; Menezes P; Prince HM; Patterson KB; Fransen K; Crucitti T; De Baetselier I; Van Damme L; Kashuba AD J Acquir Immune Defic Syndr; 2013 Mar; 62(3):260-6. PubMed ID: 23111578 [TBL] [Abstract][Full Text] [Related]
11. Population Pharmacokinetics Modeling of Unbound Efavirenz, Atazanavir, and Ritonavir in HIV-Infected Subjects With Aging Biomarkers. Dumond JB; Chen J; Cottrell M; Trezza CR; Prince H; Sykes C; Torrice C; White N; Malone S; Wang R; Patterson KB; Sharpless NE; Forrest A CPT Pharmacometrics Syst Pharmacol; 2017 Feb; 6(2):128-135. PubMed ID: 28032946 [TBL] [Abstract][Full Text] [Related]
12. Tenofovir, emtricitabine intracellular and plasma, and efavirenz plasma concentration decay following drug intake cessation: implications for HIV treatment and prevention. Jackson A; Moyle G; Watson V; Tjia J; Ammara A; Back D; Mohabeer M; Gazzard B; Boffito M J Acquir Immune Defic Syndr; 2013 Mar; 62(3):275-81. PubMed ID: 23274933 [TBL] [Abstract][Full Text] [Related]
13. Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure. Castillo-Mancilla JR; Zheng JH; Rower JE; Meditz A; Gardner EM; Predhomme J; Fernandez C; Langness J; Kiser JJ; Bushman LR; Anderson PL AIDS Res Hum Retroviruses; 2013 Feb; 29(2):384-90. PubMed ID: 22935078 [TBL] [Abstract][Full Text] [Related]
14. Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial. Mulligan K; Glidden DV; Anderson PL; Liu A; McMahan V; Gonzales P; Ramirez-Cardich ME; Namwongprom S; Chodacki P; de Mendonca LM; Wang F; Lama JR; Chariyalertsak S; Guanira JV; Buchbinder S; Bekker LG; Schechter M; Veloso VG; Grant RM; Clin Infect Dis; 2015 Aug; 61(4):572-80. PubMed ID: 25908682 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic Model of Tenofovir and Emtricitabine and Their Intracellular Metabolites in Patients in the ANRS 134-COPHAR 3 Trial Using Dose Records. Bertrand J; Barrail-Tran A; Fayette L; Savic R; Goujard C; Teicher E; Barau C; Pruvost A; Taburet AM; Mentré F; Verstuyft C Antimicrob Agents Chemother; 2023 May; 67(5):e0233918. PubMed ID: 37098914 [TBL] [Abstract][Full Text] [Related]
16. InterPrEP: internet-based pre-exposure prophylaxis with generic tenofovir disoproxil fumarate/emtrictabine in London - analysis of pharmacokinetics, safety and outcomes. Wang X; Nwokolo N; Korologou-Linden R; Hill A; Whitlock G; Day-Weber I; McClure MO; Boffito M HIV Med; 2018 Jan; 19(1):1-6. PubMed ID: 28657199 [TBL] [Abstract][Full Text] [Related]
17. Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial. Vincent KL; Moss JA; Marzinke MA; Hendrix CW; Anton PA; Pyles RB; Guthrie KM; Dawson L; Olive TJ; Butkyavichene I; Churchman SA; Cortez JM; Fanter R; Gunawardana M; Miller CS; Yang F; Rosen RK; Vargas SE; Baum MM PLoS Med; 2018 Sep; 15(9):e1002655. PubMed ID: 30265679 [TBL] [Abstract][Full Text] [Related]
18. Brief Report: Urine Emtricitabine and Tenofovir Concentrations Provide Markers of Recent Antiretroviral Drug Exposure Among HIV-Negative Men Who Have Sex With Men. Haaland RE; Martin A; Livermont T; Fountain J; Dinh C; Holder A; Lupo LD; Hall L; Conway-Washington C; Kelley CF J Acquir Immune Defic Syndr; 2019 Nov; 82(3):252-256. PubMed ID: 31335590 [TBL] [Abstract][Full Text] [Related]
19. Plasma and intracellular pharmacokinetics of tenofovir in patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide. Podany AT; Bares SH; Havens J; Dyavar SR; O'Neill J; Lee S; Fletcher CV; Swindells S; Scarsi KK AIDS; 2018 Mar; 32(6):761-765. PubMed ID: 29334548 [TBL] [Abstract][Full Text] [Related]
20. The Lymphoid Tissue Pharmacokinetics of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide in HIV-Infected Persons. Fletcher CV; Podany AT; Thorkelson A; Winchester LC; Mykris T; Anderson J; Jorstad S; Baker JV; Schacker TW Clin Pharmacol Ther; 2020 Nov; 108(5):971-975. PubMed ID: 32385902 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]